Search filters

List of works by Barbara Eichhorst

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate endpoint in CLL.

scientific article published on 18 December 2017

Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).

scientific article published on 02 September 2015

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).

scientific article published on 25 November 2016

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia

scientific article published on 8 December 2015

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

scientific article published on 13 August 2018

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial

scientific article published on 27 February 2020

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia

scientific article published on 21 February 2018

COVID-19 among fit patients with CLL treated with venetoclax-based combinations

scientific article published on 29 June 2020

COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia

scientific article published on 23 June 2020

Chronic lymphocytic leukaemia

scientific article published on 21 February 2018

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia

scientific article published on 20 February 2018

Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia

scientific article published on 20 November 2015

Current strategies to create tailored and risk-adapted therapies for CLL patients

scientific article

Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?

scientific article published in May 2016

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

scientific article

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia

scientific article published on 29 December 2020

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

scientific article published on 18 February 2020

Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective

scientific article

Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota

scientific article published on 22 April 2016

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

scientific article published on 25 April 2019

Emerging therapies for refractory chronic lymphocytic leukemia

scientific article published on 27 June 2014

Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group

scientific article published on 17 September 2015

Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual

scientific article published in December 2013

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia

scientific article published on 29 June 2016

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

scientific article published on 13 December 2019

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri

scientific article published on 20 May 2016

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study ⬇️

scientific article published on 03 December 2018

Frontline therapy for chronic lymphocytic leukemia patients

scientific article published on 01 October 2009

Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia

scientific article published on 14 March 2018

High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

scientific article published on 01 March 2020

Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study

scientific article published on 22 October 2019

Individualizing Treatment Decisions for Older Adults with Hematologic Malignancies ⬇️

scientific article published on January 1, 2013

Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

scientific article published on 14 November 2019

Initial therapy of chronic lymphocytic leukemia

scientific article published on 9 February 2016

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials

scientific article

Invasive Aspergillosis in Patients Treated With Ibrutinib

scientific article published on 13 February 2020

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study

scientific article published on 12 September 2017

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

scientific article published on 27 January 2020

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

scientific article published on 20 October 2015

Management of unfit elderly patients with chronic lymphocytic leukemia

scientific article published on 01 December 2018

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

scientific article published on 29 August 2016

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

scientific article published on 09 August 2019

Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)

scientific article published on 08 July 2019

NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib

scientific article published on 18 September 2017

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance

scientific article published on 20 September 2018

New treatment approaches in CLL: Challenges and opportunities in the elderly

scientific article

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

scientific article published on 27 August 2015

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia

scientific article published on 21 November 2018

Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL

scientific article published on 12 July 2019

Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia

scientific article

Pembrolizumab in relapsed or refractory Richter syndrome

scientific article published on 16 June 2020

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

scientific article published on 14 May 2019

Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation

scientific article

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

scientific article published on 23 March 2020

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)

scientific article published on 26 December 2019

Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

scientific article published on 10 February 2020

Prognostication of chronic lymphocytic leukemia in the era of new agents

scientific article

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

scientific article published on 01 December 2019

Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL).

scientific article published in September 2007

Second cancers in chronic lymphocytic leukemia: growing importance in the era of improved treatment outcomes

scientific article published on 12 May 2015

Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

scientific article published on 12 June 2013

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia

scientific article published on 04 October 2019

Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia

scientific article published on 19 March 2013

Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia

scientific article published on 25 March 2019

Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials

scientific article published on 01 May 2019

State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia

scientific article

TP53 mutation and survival in chronic lymphocytic leukemia

scientific article

Targeted Therapy of CLL.

scientific article published on 15 November 2016

The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression

scientific article

The Treatment of Chronic Lymphatic Leukemia

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

scientific article published on 19 August 2019

Treatment of elderly patients with chronic lymphocytic leukemia

scientific article published on February 2009

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

scientific article published on 28 September 2020

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

scientific article published on 04 June 2019

Venetoclax and obinutuzumab in chronic lymphocytic leukemia

scientific article published on 21 March 2017

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

scientific article published in May 2018

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

scientific article

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)

scientific article published on 29 October 2020

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

scientific article published on 01 September 2020

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia

scholarly article by Othman Al-Sawaf et al published May 2019 in Haematologica

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

scientific article published in March 2018

[Chronic lymphocytic leukemia]

scientific article published on 01 March 2020

[Current diagnosis and treatment of chronic lymphocytic leukaemia]

scientific article published on 13 August 2020

[Individualized Treatment of Chronic Lymphocytic Leukemia (CLL)]

scientific article published on 10 September 2018

Paulina is supported by:

About Paulina

Help